ImmunoGen Needs To Make The Most Of Its First-Mover Opportunity
Seeking Alpha,
Follow Summary Shares have lost over a third of their value in 2022. Elahere recently received accelerated approval in FRα-high…
Follow Summary Shares have lost over a third of their value in 2022. Elahere recently received accelerated approval in FRα-high…
Folate receptor α may be an important treatment target for ovarian tumors. The standard of care for epithelial ovarian cancer (EO…
The antibody-drug conjugate farletuzumab ecteribulin demonstrated notable antitumor activity with a manageable safety profile…
The FDA's thinking on Aduhelm The FDA released documents that shed light on the how the agency came to its recent decision to…